A proof‐of‐concept combined therapy study using the nonsteroidal FXR agonist cilofexor (GS‐9674) and the ACC inhibitor firsocostat (GS‐0976) was launched in patients with NASH. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.